Literature DB >> 10965493

Human breast carcinoma cells express type II IL-4 receptors and are sensitive to antitumor activity of a chimeric IL-4-Pseudomonas exotoxin fusion protein in vitro and in vivo.

P Leland1, J Taguchi, S R Husain, R J Kreitman, I Pastan, R K Puri.   

Abstract

BACKGROUND: Human breast carcinoma cell lines express high-affinity interleukin-4 receptors (IL-4R). We examined the expression and structure of these receptors on primary and cultured breast carcinoma cell lines and normal breast epithelial cells. We also tested the antitumor activity in vitro and in vivo of a fusion protein comprised of circular permuted IL-4 and truncated Pseudomonas exotoxin, termed IL-4(38-37)-PE38KDEL.
MATERIALS AND METHODS: Eight different primary cell cultures and cell lines of human breast carcinomas were examined for the expression of IL-4R by radiolabeled binding, reverse transcription polymerase chain reaction (RT-PCR) and Northern analyses, and subunit structure by crosslinking studies. The antitumor activity of IL-4 toxin was tested in vitro by cytotoxicity assays and in vivo in a xenograft model in immunodeficient animals.
RESULTS: 125I-IL-4 specifically bound to primary cell cultures and cell lines with a Kd ranging between 0.2 and 1 nM. Breast tumor cells were found to express IL-4R beta and IL-13R alpha' chains, but not IL-2R gamma c chain. These cells were highly sensitive to the cytotoxic effect of IL-4(38-37)-PE38KDEL. The IC50 (concentration inhibiting protein synthesis by 50%) ranged between approximately 0.005-1.5 nM. A normal breast epithelial cell culture was not sensitive to the cytotoxic activity of IL-4(38-37)-PE38KDEL. MDA-MB231 human breast carcinoma cell line formed a rapidly growing tumor in nude mice. Intratumor and intraperitoneal administration of IL-4(38-37)-PE38KDEL caused a dose dependent regression of established tumors. A control toxin, anti-Tac(Fv)-PE38KDEL, targeted to the IL-2 receptor alpha chain did not cause regression of these tumors.
CONCLUSIONS: These results suggest that IL-4(38-37)-PE38KDEL may be a useful agent for targeting of IL-4 receptor positive human breast carcinomas and further studies should be performed to explore fully its potential.

Entities:  

Mesh:

Substances:

Year:  2000        PMID: 10965493      PMCID: PMC1949945     

Source DB:  PubMed          Journal:  Mol Med        ISSN: 1076-1551            Impact factor:   6.376


  16 in total

1.  Microcin E492, a channel-forming bacteriocin from Klebsiella pneumoniae, induces apoptosis in some human cell lines.

Authors:  Claudio Hetz; María Rosa Bono; Luis Felipe Barros; Rosalba Lagos
Journal:  Proc Natl Acad Sci U S A       Date:  2002-03-05       Impact factor: 11.205

2.  Interleukin-4 receptor-targeted liposomal doxorubicin as a model for enhancing cellular uptake and antitumor efficacy in murine colorectal cancer.

Authors:  Chih-Yung Yang; Hong-Wen Liu; Ya-Ching Tsai; Ju-Yu Tseng; Shu-Ching Liang; Chin-Yau Chen; Wei-Nan Lian; Ming-Cheng Wei; Maggie Lu; Ruey-Hwa Lu; Chi-Hung Lin; Jeng-Kai Jiang
Journal:  Cancer Biol Ther       Date:  2015-10-05       Impact factor: 4.742

3.  A new effect of IL-4 on human γδ T cells: promoting regulatory Vδ1 T cells via IL-10 production and inhibiting function of Vδ2 T cells.

Authors:  Yujia Mao; Shanshan Yin; Jianmin Zhang; Yu Hu; Bo Huang; Lianxian Cui; Ning Kang; Wei He
Journal:  Cell Mol Immunol       Date:  2015-03-16       Impact factor: 11.530

Review 4.  Alternative activation of tumor-associated macrophages by IL-4: priming for protumoral functions.

Authors:  Hao-Wei Wang; Johanna A Joyce
Journal:  Cell Cycle       Date:  2010-12-15       Impact factor: 4.534

Review 5.  Targeting IL4/IL4R for the treatment of epithelial cancer metastasis.

Authors:  Katherine Venmar Bankaitis; Barbara Fingleton
Journal:  Clin Exp Metastasis       Date:  2015-09-18       Impact factor: 5.150

6.  A novel reduced immunogenicity bispecific targeted toxin simultaneously recognizing human epidermal growth factor and interleukin-4 receptors in a mouse model of metastatic breast carcinoma.

Authors:  Seunguk Oh; Brad J Stish; Deepali Sachdev; Hua Chen; Arkadiusz Z Dudek; Daniel A Vallera
Journal:  Clin Cancer Res       Date:  2009-09-29       Impact factor: 12.531

Review 7.  Interleukin-4-Pseudomonas exotoxin chimeric fusion protein for malignant glioma therapy.

Authors:  Mariko Kawakami; Koji Kawakami; Raj K Puri
Journal:  J Neurooncol       Date:  2003-10       Impact factor: 4.130

8.  Aerosol delivery of small hairpin osteopontin blocks pulmonary metastasis of breast cancer in mice.

Authors:  Kyeong-Nam Yu; Arash Minai-Tehrani; Seung-Hee Chang; Soon-Kyung Hwang; Seong-Ho Hong; Ji-Eun Kim; Ji-Young Shin; Sung-Jin Park; Ji-Hye Kim; Jung-Taek Kwon; Hu-Lin Jiang; Bitna Kang; Duyeol Kim; Chan-Hee Chae; Kee-Ho Lee; Tae-Jong Yoon; George R Beck; Myung-Haing Cho
Journal:  PLoS One       Date:  2010-12-22       Impact factor: 3.240

9.  Therapeutic efficacy of Cintredekin Besudotox (IL13-PE38QQR) in murine lung fibrosis is unaffected by immunity to Pseudomonas aeruginosa exotoxin A.

Authors:  Rogério S Rosada; Ana P Moreira; Fabiani G Frantz; Raj K Puri; Aquilur Rahman; Theodore J Standiford; Carlos R Zárate-Bladés; Célio L Silva; Cory M Hogaboam
Journal:  PLoS One       Date:  2010-01-15       Impact factor: 3.752

10.  Affitoxin--a novel recombinant, HER2-specific, anticancer agent for targeted therapy of HER2-positive tumors.

Authors:  Rafal Zielinski; Ilya Lyakhov; Amy Jacobs; Oleg Chertov; Gabriela Kramer-Marek; Nicholas Francella; Andrew Stephen; Robert Fisher; Robert Blumenthal; Jacek Capala
Journal:  J Immunother       Date:  2009-10       Impact factor: 4.912

View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.